Trial intelligence / Profile preview

Pentoxifylline and Colchicine for Treatment of Covid-19

IRCT20200721048159N3Phase 3Completed

Sponsor
Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences
Start
Jun 2021
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3 trial of pentoxifylline and colchicine in coronavirus disease 2019 (COVID-19), sponsored by Vice Chancellor for Research and Technology of Lorestan University of Medical Sciences. Started Jun 2021; status: completed.

02

Drugs

pentoxifyllinecolchicine
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on IRCT20200721048159N3.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20200721048159N3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call